Its selective biochemical profile and favorable safety characteristics make it suitable for advanced studies on NAD+ metabolism, mitochondrial function, and metabolic health
In clinical trials of Wegovy (FDA-approved semaglutide), participants achieved an average weight loss of approximately 15% over 68 weeks, with some participants achieving up to 20% with continued treatment and adherence, when combined with diet and exercise
By bypassing the gastrointestinal tract, vitamin B12 injections effectively restore normal levels of the vitamin, alleviating symptoms and preventing complications
We customize B12 IV therapy for each patient
No subscription or membership required
Ingredients: Active Ingredient: Hydroxocobalamin (1000 mcg per mL)